These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38200586)

  • 1. Machine learning prediction of pathological complete response and overall survival of breast cancer patients in an underserved inner-city population.
    Dell'Aquila K; Vadlamani A; Maldjian T; Fineberg S; Eligulashvili A; Chung J; Adam R; Hodges L; Hou W; Makower D; Duong TQ
    Breast Cancer Res; 2024 Jan; 26(1):7. PubMed ID: 38200586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features.
    Meti N; Saednia K; Lagree A; Tabbarah S; Mohebpour M; Kiss A; Lu FI; Slodkowska E; Gandhi S; Jerzak KJ; Fleshner L; Law E; Sadeghi-Naini A; Tran WT
    JCO Clin Cancer Inform; 2021 Jan; 5():66-80. PubMed ID: 33439725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
    Warner ET; Ballman KV; Strand C; Boughey JC; Buzdar AU; Carey LA; Sikov WM; Partridge AH
    Breast Cancer Res Treat; 2016 Aug; 159(1):109-18. PubMed ID: 27449492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer.
    Bitencourt AGV; Gibbs P; Rossi Saccarelli C; Daimiel I; Lo Gullo R; Fox MJ; Thakur S; Pinker K; Morris EA; Morrow M; Jochelson MS
    EBioMedicine; 2020 Nov; 61():103042. PubMed ID: 33039708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Haque W; Verma V; Hatch S; Suzanne Klimberg V; Brian Butler E; Teh BS
    Breast Cancer Res Treat; 2018 Aug; 170(3):559-567. PubMed ID: 29693228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
    Zhu Q; Tannenbaum S; Kurtzman SH; DeFusco P; Ricci A; Vavadi H; Zhou F; Xu C; Merkulov A; Hegde P; Kane M; Wang L; Sabbath K
    Breast Cancer Res; 2018 Jun; 20(1):56. PubMed ID: 29898762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival.
    Orsaria P; Grasso A; Ippolito E; Pantano F; Sammarra M; Altomare C; Cagli B; Costa F; Perrone G; Soponaru G; Caggiati L; Vanni G; Buonomo OC; Altomare V
    Anticancer Res; 2021 May; 41(5):2697-2709. PubMed ID: 33952501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Braman NM; Etesami M; Prasanna P; Dubchuk C; Gilmore H; Tiwari P; Plecha D; Madabhushi A
    Breast Cancer Res; 2017 May; 19(1):57. PubMed ID: 28521821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
    Parise C; Caggiano V
    Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study.
    Sarma M; Perimbeti S; Nasir S; Attwood K; Kapoor A; O'Connor T; Early A; Levine EG; Takabe K; Kalinski P; Ambrosone C; Khoury T; Yao S; Gandhi S
    Breast Cancer Res Treat; 2022 Apr; 192(2):411-421. PubMed ID: 35000093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning on MRI radiomic features: identification of molecular subtype alteration in breast cancer after neoadjuvant therapy.
    Liu HQ; Lin SY; Song YD; Mai SY; Yang YD; Chen K; Wu Z; Zhao HY
    Eur Radiol; 2023 Apr; 33(4):2965-2974. PubMed ID: 36418622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
    Kim JY; Jeon E; Kwon S; Jung H; Joo S; Park Y; Lee SK; Lee JE; Nam SJ; Cho EY; Park YH; Ahn JS; Im YH
    Breast Cancer Res Treat; 2021 Oct; 189(3):747-757. PubMed ID: 34224056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
    Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
    Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US.
    Shubeck S; Zhao F; Howard FM; Olopade OI; Huo D
    JAMA Netw Open; 2023 Mar; 6(3):e235834. PubMed ID: 36995711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Value of Breast MRI Background Parenchymal Enhancement for Neoadjuvant Treatment Response among HER2- Patients.
    Arasu VA; Kim P; Li W; Strand F; McHargue C; Harnish R; Newitt DC; Jones EF; Glymour MM; Kornak J; Esserman LJ; Hylton NM;
    J Breast Imaging; 2020 Aug; 2(4):352-360. PubMed ID: 32803155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.